Ropeginterferon Alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C
نویسندگان
چکیده
منابع مشابه
Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.
The objectives of this study were to assess the safety and efficacy of darbepoetin alfa (Aranesp) administered every 2 weeks in anemic patients with solid tumors receiving chemotherapy. This was an open-label, randomized, active-controlled, multicenter dose-finding study evaluating a range of every-2-week darbepoetin alfa doses. The active control arm received epoetin alfa (Epogen, Procrit) at ...
متن کاملPeginterferon alfa-2b and ribavirin therapy in Kuwaiti patients with chronic hepatitis C virus infection.
Few studies have been conducted in the Eastern Mediterranean region on chronic hepatitis C virus (HCV) infection with reference to genotypes. We investigated the response to standard combination therapy (pegylated interferon/ribavirin) of different genotypes of HCV in Kuwaiti patients and factors that could be associated with sustained virological response (SVR). The records of all Kuwaiti pati...
متن کاملTreatment of chronic hepatitis C with recombinant interferon alfa-2b for nine months.
This randomised, controlled trial was designed to assess the response to a nine month course of interferon (IFN) alfa-2b, starting with a higher than usual dose. Forty eight patients received IFN 5 million units (MU) three times a week for eight weeks followed by 3 MU three times weekly for seven months; 25 patients in the control group received no treatment. The overall response to treatment w...
متن کاملEfficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
INTRODUCTION Treatment of chronic hepatitis C (CHC) with pegylated interferon (Peg-IFN) and ribavirin leads to sustained virological response (SVR) in approximately 50% of the patients. SVR depends on hepatitis C virus (HCV) and host factors, including IL28B genotypes. OBJECTIVES The aim of the study was to investigate the therapeutic efficacy of the difficult-to-treat HCV genotype 1b in pati...
متن کاملTreatment of acute hepatitis C with interferon alfa-2b.
BACKGROUND In people who are infected with the hepatitis C virus (HCV) chronic infection often develops and is difficult to eradicate. We sought to determine whether treatment during the acute phase could prevent the development of chronic infection. METHODS Between 1998 and 2001, we identified 44 patients throughout Germany who had acute hepatitis C. Patients received 5 million U of interfer...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the Formosan Medical Association
سال: 2021
ISSN: 0929-6646
DOI: 10.1016/j.jfma.2020.09.018